Magneto Thrombectomy Solutions’ eTrieve Catheter for PE Evaluated in FIH Study in Europe

May 10, 2022—Magneto Thrombectomy Solutions, an Israel-based medical device company developing thrombectomy solutions for the treatment of ischemic stroke and pulmonary embolism (PE), announced that first-in-human (FIH) results demonstrated safety and feasibility of the company’s eTrieve system in patients with acute PE. The data showed a significant reduction in right ventricular to left ventricular (RV/LV) ratio and alleviation of PE associated symptoms.

The data were presented at Biomed Israel 2022, an international Life Science and HealthTech conference held May 10-12 in Tel Aviv, Israel.

Magneto’s eTrieve catheter utilizes the electric properties of blood clots. When voltage is applied to the catheter, the negatively charged clot bonds to the positively charged electrode of the catheter, creating a strong grip, and allowing safe removal of the clot.

According to the company, the prospective, single-arm, multicenter FIH study assessed the initial safety and performance of eTrieve in treating patients with acute PE. The study enrolled 10 patients at three sites in Denmark and Poland. The procedures were performed under light sedation.

Magneto reported the following results:

• The procedure was safe with no device-related complications.
• The primary performance endpoint was met, with significant reduction of RV/LV volume at 48 hours postintervention.
• Significant clot volumes were removed, and alleviation of PE-associated symptoms was demonstrated.
• The catheter removed both fresh and organized clots and successfully removed blood clots of all sizes and types, from locations that could not have been safely reached using other techniques.

Professor Asger Andersen, MD, the study’s Principal Investigator with Aarhus University Hospital, Aarhus, Denmark, and Professor Piotr Musialek, MD, an investigator in the study with John Paul II Hospital in Krakow, Poland, discussed the device and the FIH findings in the company’s press release.

“Magneto provides intermediate and high-risk PE patients with a unique solution for safely and effectively removing large clots blocking the arteries in the lungs,” commented Prof. Musialek. “The combination of a large-diameter ‘vacuum cleaner’ with electro-mechanical thrombus extraction, allows an immediate resolution of dyspnea and swift recovery of the cardio-respiratory system.”

Prof. Andersen added, “Large-bore aspiration of central clots with possibility to retrieve segmental clots with the eTrieve catheter optimizes the possibility for complete pulmonary revascularization in acute PE.”

Benny Dilmoney, CEO of Magneto, stated in the press release, “We are very pleased with our FIH results, which confirm the safety and efficiency of our innovative technology, as previously demonstrated in preclinical studies. Our novel catheter is a groundbreaking solution that can transform treatment of conditions caused by blood clots, such as PE. The technology generates strong attachment forces between the eTrieve catheter and the clot, allowing the effective removal of the clot without applying outward radial forces against the vessel wall, minimizing bleeding, and enabling removal of both proximal and distal clots. We believe that our novel solution will be a game changer in removing clots and helping people recover safely from life-threatening conditions such as PE.”

Further, Mr. Dilmoney noted, “We look forward to initiating our pivotal study on more than 100 patients in multiple medical centers in the United States and Europe, planned for later this year.”

Magneto was established as part of Incentive, Peregrine Ventures’ incubator, by Chief Technical Officer and Founder Yuval Taff. The technology was developed by Professor Itzhak Orion, PhD, and licensed from BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev in Beersheba, Israel.